Leap Therapeutics, INC Form 4 insider transactions

Cypherpunk Technologies director Oei Khing Djien reports changes in restricted stock unit holdings, including a new award to CoinXit Ltd.

Winklevoss Capital Fund and related entities reported the assignment of over 5.6 million Cypherpunk Technologies warrants, exercisable at $0.5335, with an ownership cap.

A director and officer of Cypherpunk Technologies Inc. reported significant sales of common stock by affiliated entities as part of their liquidation process.

Christopher Mirabelli, a director of Cypherpunk Technologies Inc., sold 676,319 shares of common stock at $3.14 per share as part of liquidating distributions from two investment entities.

A trust associated with Cypherpunk Technologies Inc. Director James H. Cavanaugh sold 261,840 common shares at a weighted average price of $3.14 as part of a liquidation.

Cypherpunk Technologies Inc. CEO Douglas E. Onsi received a grant of 2,087,287 restricted stock units, aligning his long-term interests with shareholder value.

Cypherpunk Technologies Inc. Director William Li was awarded 74,700 restricted stock units, vesting immediately, under the company's 2022 Equity Incentive Plan.

Cypherpunk Technologies Inc. director Richard Christian M received 74,700 restricted stock units, vesting immediately, as part of the company's 2022 Equity Incentive Plan.

Cypherpunk Technologies Inc. director Nissim Mashiach received an award of 74,700 restricted stock units, vesting immediately.

Cypherpunk Technologies Director Patricia A. Martin received 74,700 restricted stock units under the company's 2022 Equity Incentive Plan.

Cypherpunk Technologies Director Richard Schilsky received 74,700 restricted stock units, vesting immediately, as part of the company's 2022 Equity Incentive Plan.

Cypherpunk Technologies Inc. director Joseph Loscalzo received 74,700 restricted stock units, vesting immediately upon issuance.

Cypherpunk Technologies Inc. director James H. Cavanaugh was awarded 74,700 restricted stock units, vesting immediately.

Cypherpunk Technologies Director Christopher Mirabelli received 74,700 restricted stock units, vesting immediately, as part of the company's 2016 Equity Incentive Plan.

Cypherpunk Technologies Inc. director Thomas John Dietz was granted 83,000 restricted stock units, vesting immediately.

Cypherpunk Technologies Director Khing Djien Oei reported the acquisition of over 2.4 million Restricted Stock Units, both directly and indirectly through CoinXit Ltd.

Jason Baum, Chief Scientific Officer of Leap Therapeutics, Inc., is no longer serving in his role effective June 30, 2025, and will cease Section 16 reporting obligations.

Augustine Lawlor has ceased serving as Chief Operating Officer of Leap Therapeutics, Inc., effective June 30, 2025, and is no longer subject to Section 16 reporting requirements.

John Mark O'Mahony, Chief Manufacturing Officer of Leap Therapeutics, Inc., is no longer serving in his role, effective June 30, 2025, and will cease Section 16 reporting obligations.

CEO Douglas Onsi reports the settlement of restricted stock units and adjustments to shareholdings following a reverse stock split.

Christine Granfield, VP at Leap Therapeutics, settled restricted stock units on March 28, 2025, resulting in adjustments to her beneficial ownership of common stock.

Jason Baum, Chief Scientific Officer of Leap Therapeutics, settles restricted stock units, resulting in the issuance and withholding of common stock to cover tax obligations.

Augustine Lawlor, COO of Leap Therapeutics, settled restricted stock units on March 28, 2025, resulting in adjustments to his directly and indirectly held shares of common stock.

John Mark O'Mahony, Chief Manufacturing Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025, receiving an equivalent number of common stock shares.

Christopher Mirabelli, Chairman of the Board at Leap Therapeutics, settled restricted stock units (RSUs) and adjusted his beneficial ownership of company stock.

Cynthia Sirard, Chief Medical Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) on March 28, 2025, receiving an equivalent number of common stock shares.

James Cavanaugh, a director at Leap Therapeutics, exercised warrants to purchase 213 shares of common stock at $2.82 per share.

Douglas Onsi, a key executive at Leap Therapeutics, reported the exercise of a warrant and changes in beneficial ownership of common stock.

Augustine Lawlor, Chief Operating Officer of Leap Therapeutics, indirectly acquired 2,136 shares of common stock through the exercise of a warrant by Nine Capital Partners, LLC.

Christopher Mirabelli, a director at Leap Therapeutics, exercised warrants to acquire 2,136 shares of common stock at $2.82 per share.